Drug Profile

Research programme: angiogenesis inhibitors - InMed Pharmaceuticals

Latest Information Update: 18 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cannabis Technologies
Developer InMed Pharmaceuticals
Class Antineoplastics; Cannabinoids
Mechanism of Action Angiogenesis inhibitors; Cannabinoid receptor modulators; Gene expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

03 Nov 2021 InMed Pharmaceuticals has patent protection for manufacturing and formulation of cannabinoids
28 Jul 2018 No recent reports of development identified for research development in Cancer in Canada
23 Oct 2014 InMed Pharmaceuticals enters into a strategic collaboration with the researchers at the University of British Columbia to develop a drug delivery technology for its therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com